Idiopathic Pulmonary Fibrosis: Recent Trials and Current Drug Therapy

Publisher： Karger

E-ISSN： 1423-0356|86|5|353-363

ISSN： 0025-7931

Source： Respiration, Vol.86, Iss.5, 2013-11, pp. : 353-363

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New approaches to the design of clinical trials in idiopathic pulmonary fibrosis

By Cerri Stefania   Del Giovane Cinzia   Balduzzi Sara   Soncini Francesco   Sdanganelli Antonia   Richeldi Luca  

Clinical Investigation, Vol. 3, Iss. 6, 2013-06 ,pp. : 531-544

Future Science

Access to resources Recommend Favorite

Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point

By Spagnolo Paolo   Luppi Fabrizio  

Clinical Investigation, Vol. 3, Iss. 12, 2013-12 ,pp. : 1139-1146

Future Science

Access to resources Recommend Favorite

Drug-Induced Pneumonitis Associated with Imatinib Mesylate in a Patient with Idiopathic Pulmonary Fibrosis

By  

Respiration, Vol. 75, Iss. 3, 2006-01 ,pp. : 350-354

Karger

Access to resources Recommend Favorite

Interferon gamma-1b as Therapy for Idiopathic Pulmonary Fibrosis

By  

Respiration, Vol. 71, Iss. 1, 2004-02 ,pp. : 77-82

Karger

Access to resources Recommend Favorite

Pharmacological Therapy Does Not Contribute to Survival in Idiopathic Pulmonary Fibrosis

By  

Respiration, Vol. 86, Iss. 1, 2013-04 ,pp. : 86-87

Karger

Access to resources Recommend Favorite